🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "significant breakthrough" in the fight against drug-resistant strains of the pathogen, according to researchers.

An International Health Concern

Cases of gonorrhoea are increasing worldwide, with figures suggesting more than 82 million instances per year. Notably increased rates are seen in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the reality of rising global incidence, escalating drug resistance and the highly restricted treatment choices presently on offer.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has designated it as a "priority pathogen". A tracking program revealed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Gain Clearance

Zoliflodacin, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in recent days for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers hope that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GSK, gained clearance in close succession. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone signifies a significant shift in the management of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Data and Global Access

Based on findings detailed in a major medical journal, the new drug cured the vast majority of cases of the STI. This places it at an similar efficacy with the existing first-line therapy, which uses an injection and a pill. The trial included hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the rights to make available and distribute the drug in a wide range of developing nations.

Doctors on the front lines have shared hope. Access to a single-dose, oral treatment like this is hailed as a "game-changer" for gonorrhoea control. This is deemed vital to lessen the impact of the infection for people and to prevent the spread of extremely resistant gonorrhoea around the world.